The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients
Nephro-Urology Monthly · 2022
DOI: 10.5812/numonthly-121819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephro-Urology Monthly, 2022. Verfasst von Tahereh Sabaghian und 5 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
: Considering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regression model, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.
Zitieren
APA
Sabaghian, T., Almasi, M. H., Futuhi, F., Shabani, M., Erfanifar, A., & Ebadi, S. A. (2022). The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients. Nephro-Urology Monthly. https://doi.org/10.5812/numonthly-121819
Vancouver
Sabaghian T, Almasi MH, Futuhi F, Shabani M, Erfanifar A, Ebadi SA. The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients. Nephro-Urology Monthly. 2022. doi:10.5812/numonthly-121819
BibTeX
@article{Sabaghian2022,
author = {Sabaghian, Tahereh and Almasi, Minoo Heidari and Futuhi, Farzaneh and Shabani, Minoosh and Erfanifar, Azam and Ebadi, Seyed Alireza},
title = {The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients},
journal = {Nephro-Urology Monthly},
year = {2022},
doi = {10.5812/numonthly-121819}
}
EUVIMED